Pages that link to "Q45878324"
Jump to navigation
Jump to search
The following pages link to Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis (Q45878324):
Displaying 50 items.
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B (Q24234413) (← links)
- Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? (Q33904447) (← links)
- Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A. (Q34011908) (← links)
- The economics of bleeding disorders (Q34049930) (← links)
- Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health‐technology assessment (Q34094037) (← links)
- Need for Prophylactic Treatment in Adult Haemophilia A Patients (Q34139334) (← links)
- Linking medicine and economics: health economics and quality of life in haemophilia care. (Q34636921) (← links)
- A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. (Q34890523) (← links)
- Comparative effectiveness of full‐length and B‐domain deleted factor VIII for prophylaxis – a meta‐analysis (Q35106858) (← links)
- The overall effectiveness of prophylaxis in severe haemophilia (Q35106860) (← links)
- A global view on prophylaxis: possibilities and consequences (Q35112430) (← links)
- Prophylactic factor replacement in hemophilia (Q35686301) (← links)
- The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia (Q35826358) (← links)
- Optimizing factor prophylaxis for the haemophilia population: where do we stand? (Q35915686) (← links)
- Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in Taiwan (Q36463984) (← links)
- The natural evolution of haemophilia care: developing and sustaining comprehensive care globally (Q36473025) (← links)
- New treatments in hemophilia: insights for the clinician (Q36612681) (← links)
- Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A. (Q37139733) (← links)
- Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran (Q37619008) (← links)
- Current Options and New Developments in the Treatment of Haemophilia (Q37841547) (← links)
- Health technology assessment and haemophilia (Q37984093) (← links)
- Haemophilia prophylaxis: how can we justify the costs? (Q38002994) (← links)
- Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? (Q38044472) (← links)
- How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. (Q38060224) (← links)
- Changing paradigm of prophylaxis with longer acting factor concentrates (Q38206858) (← links)
- On-demand treatment in persons with severe haemophilia (Q38222575) (← links)
- COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA. (Q39129503) (← links)
- Secondary prophylaxis treatment versus on‐demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan (Q39846029) (← links)
- Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients (Q40654703) (← links)
- Clinical outcomes and resource utilization associated with haemophilia care in Europe (Q40654709) (← links)
- The measurement of indirect costs in the health economics evaluation literature. A review (Q40829084) (← links)
- Estimating unknown parameters in haemophilia using expert judgement elicitation (Q44008451) (← links)
- Prophylaxis in bleeding disorders (Q44667237) (← links)
- Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. (Q45855703) (← links)
- Medical care for haemophilia (Q45856575) (← links)
- Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study (Q45858388) (← links)
- Financial aspects of haemophilia care in Puerto Rico and other Latin American countries (Q45863754) (← links)
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). (Q45866554) (← links)
- Prophylaxis in the haemophilia population-optimizing therapy (Q45868025) (← links)
- Practice patterns in haemophilia A therapy – a survey of treatment centres in the United States (Q45868947) (← links)
- RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia (Q45869275) (← links)
- Pathogenesis of haemophilic synovitis: clinical aspects (Q45870769) (← links)
- Participation in research: the economic advantages in a haemophilia research population (Q45871223) (← links)
- Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. (Q45872785) (← links)
- Insurance, Home Therapy, and Prophylaxis in U.S. Youth with Severe Hemophilia (Q45875132) (← links)
- Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors (Q45875250) (← links)
- Long-term outcome of individualized prophylactic treatment of children with severe haemophilia (Q45875796) (← links)
- Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy (Q45879749) (← links)
- Assessing the relationship between productivity levels and severity of haemophilia (Q45879762) (← links)
- Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. (Q45883466) (← links)